Source-grounded facts extracted from Lantern Pharma Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Lantern Pharma Inc. reported financial results for the fiscal year and fourth quarter ended December 31, 2025.
“On March 30, 2026, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2025.”
Lantern Pharma Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third (33.33%) of shares entitled to vote (effective 2025-07-24).
“On July 24, 2025, the Board approved an amendment to the Company’s By-laws (the “By-laws”), effective immediately. The amendment modified the provisions for determining a quorum for a meeting of stockholders of the Company and effectively reduced the quorum requirement from a majority of the shares entitled to vote at the meeting to one-third (33.33%) of the shares entitled to vote at the meeting.”
Lantern Pharma Inc. reported financial results for the first quarter 2024.
“On May 9, 2024, Lantern Pharma Inc. (the “Company”) will issue a press release announcing its financial results for the first quarter ended March 31, 2024.”
Lantern Pharma Inc. reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
“On March 18, 2024, Lantern Pharma Inc. (the "Company") will issue a press release announcing its financial results for the fiscal year and fourth quarter ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.